Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489513 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02489513 is a Phase 1 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT02489513, a Phase 1 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The study is designed to characterize the absorption, metabolism, and excretion of AG-120 using radiolabeled drug in healthy adult male subjects to support its further development and registration.
Interventions
- DRUG [14C]-AG-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02489513
The ClinicalTrials.gov registry entry for NCT02489513 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-AG-120 is the first listed.
NCT02489513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02489513 about?
NCT02489513 is a clinical study titled "Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120". The study is designed to characterize the absorption, metabolism, and excretion of AG-120 using radiolabeled drug in healthy adult male subjects to support its further development and registration.
What is the current status of trial NCT02489513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02489513?
The interventions under investigation include: [14C]-AG-120 (DRUG).
Who is sponsoring clinical trial NCT02489513?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.